340 related articles for article (PubMed ID: 9802339)
21. Rat dihydroorotate dehydrogenase: isolation of the recombinant enzyme from mitochondria of insect cells.
Knecht W; Altekruse D; Rotgeri A; Gonski S; Löffler M
Protein Expr Purif; 1997 Jun; 10(1):89-99. PubMed ID: 9179295
[TBL] [Abstract][Full Text] [Related]
22. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.
Cherwinski HM; Cohn RG; Cheung P; Webster DJ; Xu YZ; Caulfield JP; Young JM; Nakano G; Ransom JT
J Pharmacol Exp Ther; 1995 Nov; 275(2):1043-9. PubMed ID: 7473131
[TBL] [Abstract][Full Text] [Related]
23. Malarial dihydroorotate dehydrogenase. Substrate and inhibitor specificity.
Baldwin J; Farajallah AM; Malmquist NA; Rathod PK; Phillips MA
J Biol Chem; 2002 Nov; 277(44):41827-34. PubMed ID: 12189151
[TBL] [Abstract][Full Text] [Related]
24. Mechanism of action of leflunomide in rheumatoid arthritis.
Fox RI
J Rheumatol Suppl; 1998 Jul; 53():20-6. PubMed ID: 9666414
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N-[3'-methyl-4'-(trifluoromethyl)phenyl ] propenamide and related compounds.
Kuo EA; Hambleton PT; Kay DP; Evans PL; Matharu SS; Little E; McDowall N; Jones CB; Hedgecock CJ; Yea CM; Chan AW; Hairsine PW; Ager IR; Tully WR; Williamson RA; Westwood R
J Med Chem; 1996 Nov; 39(23):4608-21. PubMed ID: 8917650
[TBL] [Abstract][Full Text] [Related]
26. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide.
Bruneau JM; Yea CM; Spinella-Jaegle S; Fudali C; Woodward K; Robson PA; Sautès C; Westwood R; Kuo EA; Williamson RA; Ruuth E
Biochem J; 1998 Dec; 336 ( Pt 2)(Pt 2):299-303. PubMed ID: 9820804
[TBL] [Abstract][Full Text] [Related]
27. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
Rückemann K; Fairbanks LD; Carrey EA; Hawrylowicz CM; Richards DF; Kirschbaum B; Simmonds HA
J Biol Chem; 1998 Aug; 273(34):21682-91. PubMed ID: 9705303
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress.
Doscas ME; Williamson AJ; Usha L; Bogachkov Y; Rao GS; Xiao F; Wang Y; Ruby C; Kaufman H; Zhou J; Williams JW; Li Y; Xu X
Neoplasia; 2014 Oct; 16(10):824-34. PubMed ID: 25379019
[TBL] [Abstract][Full Text] [Related]
29. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice.
Xu X; Blinder L; Shen J; Gong H; Finnegan A; Williams JW; Chong AS
J Immunol; 1997 Jul; 159(1):167-74. PubMed ID: 9200452
[TBL] [Abstract][Full Text] [Related]
30. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides.
Cao WW; Kao PN; Chao AC; Gardner P; Ng J; Morris RE
J Heart Lung Transplant; 1995; 14(6 Pt 1):1016-30. PubMed ID: 8719445
[TBL] [Abstract][Full Text] [Related]
31. Redoxal as a new lead structure for dihydroorotate dehydrogenase inhibitors: a kinetic study of the inhibition mechanism.
Knecht W; Löffler M
FEBS Lett; 2000 Feb; 467(1):27-30. PubMed ID: 10664450
[TBL] [Abstract][Full Text] [Related]
32. Differential susceptibility of dihydroorotate dehydrogenase/oxidase to Brequinar Sodium (NSC 368 390) in vitro.
Lakaschus G; Löffler M
Biochem Pharmacol; 1992 Mar; 43(5):1025-30. PubMed ID: 1313236
[TBL] [Abstract][Full Text] [Related]
33. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.
Herrmann ML; Schleyerbach R; Kirschbaum BJ
Immunopharmacology; 2000 May; 47(2-3):273-89. PubMed ID: 10878294
[TBL] [Abstract][Full Text] [Related]
34. Brequinar derivatives and species-specific drug design for dihydroorotate dehydrogenase.
Hurt DE; Sutton AE; Clardy J
Bioorg Med Chem Lett; 2006 Mar; 16(6):1610-5. PubMed ID: 16406782
[TBL] [Abstract][Full Text] [Related]
35. Leflunomide: mode of action in the treatment of rheumatoid arthritis.
Breedveld FC; Dayer JM
Ann Rheum Dis; 2000 Nov; 59(11):841-9. PubMed ID: 11053058
[TBL] [Abstract][Full Text] [Related]
36. Catalytic enzyme histochemistry and biochemical analysis of dihydroorotate dehydrogenase/oxidase and succinate dehydrogenase in mammalian tissues, cells and mitochondria.
Löffler M; Becker C; Wegerle E; Schuster G
Histochem Cell Biol; 1996 Feb; 105(2):119-28. PubMed ID: 8852433
[TBL] [Abstract][Full Text] [Related]
37. Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase.
Boa AN; Canavan SP; Hirst PR; Ramsey C; Stead AM; McConkey GA
Bioorg Med Chem; 2005 Mar; 13(6):1945-67. PubMed ID: 15727850
[TBL] [Abstract][Full Text] [Related]
38. Structure-activity relationship of quinoline carboxylic acids. A new class of inhibitors of dihydroorotate dehydrogenase.
Chen SF; Papp LM; Ardecky RJ; Rao GV; Hesson DP; Forbes M; Dexter DL
Biochem Pharmacol; 1990 Aug; 40(4):709-14. PubMed ID: 2386542
[TBL] [Abstract][Full Text] [Related]
39. New inhibitors of dihydroorotate dehydrogenase (DHODH) based on the 4-hydroxy-1,2,5-oxadiazol-3-yl (hydroxyfurazanyl) scaffold.
Lolli ML; Giorgis M; Tosco P; Foti A; Fruttero R; Gasco A
Eur J Med Chem; 2012 Mar; 49():102-9. PubMed ID: 22245049
[TBL] [Abstract][Full Text] [Related]
40. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
Vyas VK; Ghate M
Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]